MA53721A - Modulateurs de la monoacylglycérol lipase - Google Patents

Modulateurs de la monoacylglycérol lipase

Info

Publication number
MA53721A
MA53721A MA053721A MA53721A MA53721A MA 53721 A MA53721 A MA 53721A MA 053721 A MA053721 A MA 053721A MA 53721 A MA53721 A MA 53721A MA 53721 A MA53721 A MA 53721A
Authority
MA
Morocco
Prior art keywords
monoacylglycerol lipase
modulators
lipase modulators
monoacylglycerol
lipase
Prior art date
Application number
MA053721A
Other languages
English (en)
Inventor
Michael K Ameriks
Gang Chen
Chaofeng Huang
Brian Ngo Laforteza
Suchitra Ravula
Emma Helen Southgate
Wei Zhang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA53721A publication Critical patent/MA53721A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
MA053721A 2018-09-28 2019-09-27 Modulateurs de la monoacylglycérol lipase MA53721A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862738600P 2018-09-28 2018-09-28

Publications (1)

Publication Number Publication Date
MA53721A true MA53721A (fr) 2021-09-15

Family

ID=68109428

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053721A MA53721A (fr) 2018-09-28 2019-09-27 Modulateurs de la monoacylglycérol lipase

Country Status (26)

Country Link
US (3) US20200102303A1 (fr)
EP (1) EP3856178B1 (fr)
JP (2) JP7482116B2 (fr)
KR (1) KR102911066B1 (fr)
CN (1) CN113164459B (fr)
AU (2) AU2019350624B2 (fr)
BR (1) BR112021005896A2 (fr)
CA (1) CA3111380A1 (fr)
CL (1) CL2021000757A1 (fr)
CO (1) CO2021003944A2 (fr)
CR (1) CR20210153A (fr)
DO (1) DOP2021000051A (fr)
EA (1) EA202190886A1 (fr)
EC (1) ECSP21021381A (fr)
IL (1) IL281812A (fr)
JO (1) JOP20210058A1 (fr)
MA (1) MA53721A (fr)
MX (1) MX2021003737A (fr)
MY (1) MY205440A (fr)
NI (1) NI202100023A (fr)
PE (1) PE20211773A1 (fr)
PH (1) PH12021550659A1 (fr)
SA (2) SA521421575B1 (fr)
SG (1) SG11202102281VA (fr)
TW (1) TWI863931B (fr)
WO (1) WO2020065613A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI644671B (zh) 2013-03-14 2018-12-21 比利時商健生藥品公司 Ｐ２ｘ７調節劑
KR20210069079A (ko) 2018-09-28 2021-06-10 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제
MY205440A (en) 2018-09-28 2024-10-21 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
AU2020288559C1 (en) * 2019-06-04 2025-07-24 Hager Biosciences, Llc Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
JP7697934B2 (ja) 2019-09-30 2025-06-24 ヤンセン ファーマシューティカ エヌ．ベー． 放射線標識されたｍｇｌ ｐｅｔリガンド
BR112022019077A2 (pt) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase
WO2022150962A1 (fr) * 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Inhibiteurs de protéase, leur préparation et leurs utilisations
IL310747A (en) * 2021-08-11 2024-04-01 Landos Biopharma Inc TETRAHYDROPYRAZOLOPYRIDINE-ANALOG LIGANDS OF NLRX1 AND THEIR USES
WO2023110958A1 (fr) 2021-12-16 2023-06-22 F. Hoffmann-La Roche Ag Composés hétérocycliques bicycliques servant d'inhibiteurs de monoacylglycérol lipase
CA3242372A1 (fr) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibition de la monoacylglycerol lipase (magl)
CN115872995B (zh) * 2022-12-27 2024-10-01 上海凌凯科技股份有限公司 一种吡唑并吡啶化合物及一种羧酸衍生物的制备方法
CN116606298A (zh) * 2023-05-26 2023-08-18 康化（上海）新药研发有限公司 2,3-二氢-[1,4]二噁烷并[2,3-b]吡啶-8-羧酸的合成方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
US4816463A (en) 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
CA2093125C (fr) 1990-10-02 2003-12-16 Warner-Lambert Company Antagonistes de l'angiotensine ii
EP1526852A1 (fr) 2002-07-25 2005-05-04 Pharmacia Italia S.p.A. Bicyclo-pyrazoles actifs utiles comme inhibiteurs de kinase, leur procede de preparation et compositions pharmaceutiques les comprenant
CA2493637A1 (fr) 2002-07-25 2004-02-12 Manuela Villa Bicyclo-pyrazoles actifs inhibiteurs de kinase, procede de preparation et compositions pharmaceutiques contenant ceux-ci
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
FR2857363B1 (fr) 2003-07-10 2007-09-07 Aventis Pharma Sa 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation
AR045037A1 (es) * 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
JP2007506787A (ja) 2003-09-23 2007-03-22 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼインヒビターとしてのピラゾロピロール誘導体
EP1784188B1 (fr) 2004-08-23 2010-07-14 Merck Sharp & Dohme Corp. Derives de triazole accoles inhibiteurs de la dipeptidyl peptidase-iv utilises dans le traitement ou la prevention du diabete
WO2006080884A1 (fr) 2005-01-27 2006-08-03 Astrazeneca Ab Nouveaux composes biaromatiques, inhibiteurs du recepteur p2x7
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006110516A1 (fr) 2005-04-11 2006-10-19 Abbott Laboratories Antagonistes de l'acylhydrazide p2x7 et leurs utilisations
MX2008012617A (es) 2006-03-31 2008-10-10 Novartis Ag Compuestos organicos.
US7943617B2 (en) 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
FR2915197B1 (fr) 2007-04-18 2009-06-12 Sanofi Aventis Sa Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique.
KR20100023040A (ko) 2007-06-21 2010-03-03 쉐링 코포레이션 폴리사이클릭 구아닌 유도체 및 이의 용도
CA2691512A1 (fr) 2007-08-10 2009-02-19 H. Lundbeck A/S Analogues d'heteroarylamides
FR2921342B1 (fr) 2007-09-20 2010-03-12 Airbus France Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef
EP2090576A1 (fr) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, leur procédé de préparation et leur utilisation en tant que modulateurs des récepteurs metabotropiques du glutamate (mGluR)
KR101598397B1 (ko) 2008-04-22 2016-02-29 얀센 파마슈티카 엔.브이. 퀴놀린 또는 이소퀴놀린 치환된 피2엑스7 안타고니스트
JP5063815B2 (ja) 2008-11-25 2012-10-31 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 抗腫瘍および抗神経変性剤としての二環式ピラゾールおよびイソオキサゾール誘導体
WO2010066629A2 (fr) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Nouvelles azaindoles
JP2012524800A (ja) 2009-04-22 2012-10-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ モノアシルグリセロールリパーゼ阻害剤としてのアゼチジニルジアミド
CA2759706A1 (fr) * 2009-04-22 2010-10-28 Janssen Pharmaceutica Nv Piperazinyl azetidinyl amides heteroaromatiques et aromatiques en tant qu'inhibiteurs de la monoacylglycerol lipase
JP5654001B2 (ja) 2009-04-29 2015-01-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐ２Ｘ７調節因子としての５，６，７，８−テトラヒドロ［１，２，４］トリアゾロ［４，３−ａ］ピラジン誘導体
GB0907515D0 (en) 2009-04-30 2009-06-10 Glaxo Group Ltd Compounds
US8871760B2 (en) 2009-09-21 2014-10-28 Roche Palo Alto Llc [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
WO2011050202A1 (fr) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Composés hétérocycliques condensés en tant que modulateurs de récepteur d'orexine
WO2011103715A1 (fr) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Antagonistes de canal task
PL2552920T3 (pl) 2010-04-02 2017-08-31 Ogeda Sa Nowe wybiórcze związki antagonistów receptora NK-3, farmaceutyczne kompozycje i sposoby do zastosowania w zaburzeniach pośredniczonych przez receptory NK-3
EP2558661A4 (fr) 2010-04-16 2014-10-29 Fernandez Rodrigo Graf Structures pliables pour une construction
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2619204A4 (fr) 2010-09-21 2014-08-27 Merck Sharp & Dohme Triazolopyrazinones comme antagonistes des récepteurs p2x7
CA2810077A1 (fr) * 2010-09-27 2012-04-05 Peter J. Connolly Amides d'oxopiperazine-azetidine et amides d'oxodiazepine-azetidine utilises comme inhibiteurs de la monoacylglycerol lipase
JP2013540159A (ja) 2010-10-22 2013-10-31 ヤンセン ファーマシューティカ エヌ．ベー． モノアシルグリセロールリパーゼ阻害剤としてのピペリジン−４−イル−アゼチジンジアミド
BR112013009828A2 (pt) * 2010-10-22 2016-07-26 Janssen Pharmaceutica Nv diamidas de amino-pirrolidina-azetidina como inibidores de monoacilglicerol lipase
WO2012145581A1 (fr) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Octahydropyrrolo [3,4-c] pyrroles disubstitués utilisés comme modulateurs du récepteur de l'orexine
DK2763992T3 (en) 2011-10-03 2016-04-25 Euroscreen Sa NOVEL CHIRAL N-acyl-5,6,7, (8-substituted) -tetrahydro [1,2,4] triazolo [4,3-a] pyrazines as selective NK-3 receptor antagonists, PHARMACEUTICAL COMPOSITION AND METHODS FOR THE use in the NK-3 receptor mediated diseases
WO2013055984A1 (fr) * 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Composés tétrahydroisoquinolines substitués en tant qu'inhibiteurs du facteur xia
US9273947B2 (en) 2012-02-07 2016-03-01 Lg Innotek Co., Ltd. Sensing magnet apparatus for motor
JP5205547B1 (ja) 2012-04-20 2013-06-05 株式会社ノイズ研究所 放射信号可視化装置
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
SG11201408284VA (en) 2012-05-22 2015-02-27 Xenon Pharmaceuticals Inc N-substituted benzamides and their use in the treatment of pain
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
PE20150887A1 (es) 2012-10-15 2015-06-04 Epizyme Inc Compuestos de benceno sustituidos
US9290476B2 (en) 2012-10-16 2016-03-22 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
TWI646099B (zh) 2012-11-01 2019-01-01 英塞特控股公司 作爲ｊａｋ抑制劑之三環稠合噻吩衍生物
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
BR112015014968A2 (pt) 2012-12-21 2017-07-11 Quanticel Pharmaceuticals Inc inibidores de histona-desmetilase
MX365640B (es) 2012-12-21 2019-06-10 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones.
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
MX2015009952A (es) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
NO335177B1 (no) 2013-03-06 2014-10-13 Cambi Technology As Fremgangsmåte og anordning for termisk biologisk nedbryting og avvanning av biomasse
SMT202000084T1 (it) 2013-03-06 2020-03-13 Janssen Pharmaceutica Nv Modulatori benzoimidazol-2-il pirimidinici del recettore h4 dell'istamina
SG11201507395PA (en) 2013-03-14 2015-10-29 Curadev Pharma Private Ltd Inhibitors of the kynurenine pathway
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
TWI644671B (zh) * 2013-03-14 2018-12-21 比利時商健生藥品公司 Ｐ２ｘ７調節劑
HUE043568T2 (hu) 2013-03-14 2019-08-28 Glaxosmithkline Ip No 2 Ltd 2,3-diszubsztituált 1-acil-4-amino-1,2,3,4-tetrahidrokinolin származékok és bromodomén inhibitorokkénti felhasználásuk
KR20150126623A (ko) 2013-03-14 2015-11-12 뉴링크 제네틱스 코퍼레이션 트립토판 대사로 인한 면역억제의 억제제로서의 삼환식 화합물
ES2845473T3 (es) 2013-03-14 2021-07-26 Boehringer Ingelheim Int (Bencil-ciano-metil)-amidas sustituidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico inhibidores de la catepsina- C
US9604982B2 (en) 2013-03-14 2017-03-28 Janssen Pharmaceutica Nv P2X7 modulators
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
CA2907814C (fr) 2013-03-29 2021-07-13 Euroscreen Sa Nouvelles n-acyl-(3-substitues)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines utilisees en tant qu'antagonistes selectifs des recepteurs nk-3, composition pharmaceutique, methodes d'utilisation dans le traitement de troubles medies par les recepteurs nk-3
CN105658639A (zh) 2013-08-22 2016-06-08 豪夫迈·罗氏有限公司 炔基醇和应用方法
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
KR102455043B1 (ko) 2014-09-11 2022-10-13 얀센 파마슈티카 엔.브이. 치환된 2-아자바이사이클 및 오렉신 수용체 조절제로서의 이의 용도
AU2015315693B2 (en) 2014-09-12 2020-01-16 Janssen Pharmaceutica Nv P2X7 modulating n-acyl-triazolopyrazines
WO2016039977A1 (fr) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv Modulateurs de p2x7
WO2016109684A2 (fr) 2014-12-30 2016-07-07 Novira Therapeutics, Inc. Dérivés et méthodes de traitement d'infections provoquées par le virus de l'hépatite b
JP6653319B2 (ja) 2015-03-30 2020-02-26 武田薬品工業株式会社 複素環化合物
UA121775C2 (uk) 2015-07-31 2020-07-27 Пфайзер Інк. 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl
WO2017087858A1 (fr) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Composés de pyrazole, procédés de production et utilisation
CN108017636A (zh) 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
US10934276B2 (en) 2016-12-16 2021-03-02 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4
EP3571202B1 (fr) 2017-01-23 2021-06-30 Pfizer Inc. Composés spiro hétérocycliques utilisés en tant qu'inhibiteurs de magl
MY205440A (en) 2018-09-28 2024-10-21 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
KR20210069079A (ko) 2018-09-28 2021-06-10 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제
CN112272670B (zh) 2019-04-16 2023-12-12 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
JP7697934B2 (ja) 2019-09-30 2025-06-24 ヤンセン ファーマシューティカ エヌ．ベー． 放射線標識されたｍｇｌ ｐｅｔリガンド
BR112022019077A2 (pt) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase

Also Published As

Publication number Publication date
AU2019350624A1 (en) 2021-03-18
WO2020065613A1 (fr) 2020-04-02
AU2019350624B2 (en) 2025-07-24
EP3856178A1 (fr) 2021-08-04
AU2025226693A1 (en) 2025-09-25
KR102911066B1 (ko) 2026-01-09
JP2024096702A (ja) 2024-07-17
MY205440A (en) 2024-10-21
PH12021550659A1 (en) 2022-02-21
CN113164459B (zh) 2024-09-03
CO2021003944A2 (es) 2021-04-19
DOP2021000051A (es) 2022-05-31
MX2021003737A (es) 2021-05-14
NI202100023A (es) 2021-09-07
TW202028198A (zh) 2020-08-01
EP3856178B1 (fr) 2026-03-11
US20230145249A1 (en) 2023-05-11
CL2021000757A1 (es) 2021-08-27
SA521421575B1 (ar) 2024-08-11
JP7482116B2 (ja) 2024-05-13
BR112021005896A2 (pt) 2021-07-27
ECSP21021381A (es) 2021-04-29
US12577243B2 (en) 2026-03-17
US20200102303A1 (en) 2020-04-02
SG11202102281VA (en) 2021-04-29
CN113164459A (zh) 2021-07-23
CR20210153A (es) 2021-05-11
SA522441561B1 (ar) 2024-08-11
IL281812A (en) 2021-05-31
EA202190886A1 (ru) 2021-09-07
JOP20210058A1 (ar) 2021-03-24
PE20211773A1 (es) 2021-09-08
TWI863931B (zh) 2024-12-01
CA3111380A1 (fr) 2020-04-02
US11820766B2 (en) 2023-11-21
JP2022502424A (ja) 2022-01-11
US20220332713A1 (en) 2022-10-20
KR20210069080A (ko) 2021-06-10

Similar Documents

Publication Publication Date Title
MA53721A (fr) Modulateurs de la monoacylglycérol lipase
DK3743406T3 (da) Tmem16a modulatorer
EP3861130A4 (fr) Modulateurs génétiques modifiés
MA53722A (fr) Modulateurs de la monoacylglycérol lipase
IL283967A (en) Modulators of hsd17b13 expression
IL281492A (en) Modulators of pnpla3 expression
HUE062866T2 (hu) TREX-1 modulátorok
EP4103557C0 (fr) Modulateurs de la monoacylglycérol lipase
EP3675849A4 (fr) Modulateurs de tétrahydrocannabinol
EP3601569A4 (fr) Modulateurs de l'expression de pcsk9
DK3749669T3 (da) Ahr-modulatorer
MA53924A (fr) Modulateurs de l'expression d'apol1
HUE058145T2 (hu) Deformálható érzékelõ
MA54825A (fr) Modulateurs de gpr35
EP3821026A4 (fr) Enzymes variantes de phosphopentomutase modifiées
EP4192957A4 (fr) Modulateurs de trpml
EP3758704A4 (fr) Modulateurs de l'expression d'irf4
EP4025957C0 (fr) Modulateur électro-optique
EP4035739A4 (fr) Hydrogel
EP3777974C0 (fr) Applicateur de lumière
EP3958804A4 (fr) Applicateur de lentille
EP3779540A4 (fr) Modulateur optique
EP3954003A4 (fr) Épissure de contact
EP4022049A4 (fr) Variants de lipase modifiés
EP3994774C0 (fr) Système optique